Revised Dose Schema of Sublingual Buprenorphine in the Treatment of the Neonatal Opioid Abstinence Syndrome

Overview

Journal Addiction

Specialty Psychiatry

Date 2010 Oct 8

PMID 20925688

Citations 37

Authors

Walter K Kraft

Kevin Dysart

Jay S Greenspan

Eric Gibson

Karol Kaltenbach

Michelle E Ehrlich

Affiliations

Soon will be listed here.

Abstract

Aims: More than half of infants exposed to opioids in utero develop neonatal abstinence syndrome (NAS) of severity to require pharmacological therapy. Current treatments are associated with prolonged hospitalization. We sought to optimize the dose of sublingual buprenorphine in the treatment of NAS.

Design: Randomized, Phase 1, open-label, active-control clinical trial comparing sublingual buprenorphine to oral morphine.

Setting: Large, urban, tertiary care hospital.

Participants: Twenty-four term infants requiring pharmacological treatment for NAS.

Measurements: Outcomes were neonatal safety, length of treatment and length of hospitalization.

Findings: Sublingual buprenorphine was safe and effective. Infants treated with buprenorphine had a 23-day length of treatment compared to 38 days for those treated with morphine (P = 0.01), representing a 40% reduction. Length of hospital stay in the buprenorphine group was reduced 24%, from 42 to 32 days (P = 0.05).

Conclusions: Sublingual buprenorphine was safe in NAS, with a substantial efficacy advantage over standard of care therapy with oral morphine.

Citing Articles

Buprenorphine vs. morphine: impact on neonatal opioid withdrawal syndrome (NOWS) outcomes in a single center retrospective study.

Anbalagan S, Anderson V, Favara M, Stark D, Carola D, Solarin K J Perinatol. 2024; .

PMID: 39003405 DOI: 10.1038/s41372-024-02046-7.

Intrauterine and Neonatal Exposure to Opioids: Toxicological, Clinical, and Medico-Legal Issues.

Albano G, Spina C, Pitingaro W, Milazzo V, Triolo V, Argo A Toxics. 2023; 11(1).

PMID: 36668788 PMC: 9866828. DOI: 10.3390/toxics11010062.

Buprenorphine pharmacotherapy for the management of neonatal abstinence syndrome in methadone-exposed neonates.

Taleghani A, Isemann B, Rice W, Ward L, Wedig K, Akinbi H Paediatr Neonatal Pain. 2022; 1(2):33-38.

PMID: 35548374 PMC: 8975186. DOI: 10.1002/pne2.12008.

Buprenorphine for the Treatment of Neonatal Abstinence Syndrome.

Bishop B J Pharm Technol. 2021; 34(6):266-272.

PMID: 34861018 PMC: 6231284. DOI: 10.1177/8755122518788535.

Neonatal opioid withdrawal syndrome: a review of the science and a look toward the use of buprenorphine for affected infants.

Devlin L, Young L, Kraft W, Wachman E, Czynski A, Merhar S J Perinatol. 2021; 42(3):300-306.

PMID: 34556799 PMC: 8459143. DOI: 10.1038/s41372-021-01206-3.

References

Blaser A, Pulzer F, Knupfer M, Robel-Tillig E, Vogtmann C, Nickel P . [Drug withdrawal in newborns - clinical data of 49 infants with intrauterine drug exposure: what should be done?]. Klin Padiatr. 2008; 220(5):308-15. DOI: 10.1055/s-2007-992800. View

Coyle M, Ferguson A, LaGasse L, Oh W, Lester B . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr. 2002; 140(5):561-4. DOI: 10.1067/mpd.2002.123099. View

Crocetti M, Amin D, Jansson L . Variability in the evaluation and management of opiate-exposed newborns in Maryland. Clin Pediatr (Phila). 2007; 46(7):632-5. DOI: 10.1177/0009922807300699. View

. Neonatal drug withdrawal. American Academy of Pediatrics Committee on Drugs. Pediatrics. 1998; 101(6):1079-88. View

Agthe A, Kim G, Mathias K, Hendrix C, Chavez-Valdez R, Jansson L . Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics. 2009; 123(5):e849-56. PMC: 2746902. DOI: 10.1542/peds.2008-0978. View

Seligman N, Salva N, Hayes E, Dysart K, Pequignot E, Baxter J . Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol. 2008; 199(4):396.e1-7. DOI: 10.1016/j.ajog.2008.06.088. View

Jones H, Johnson R, Jasinski D, OGrady K, Chisholm C, Choo R . Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005; 79(1):1-10. DOI: 10.1016/j.drugalcdep.2004.11.013. View

Sarkar S, Donn S . Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol. 2005; 26(1):15-7. DOI: 10.1038/sj.jp.7211427. View

Osborn D, Jeffery H, Cole M . Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev. 2005; (3):CD002053. DOI: 10.1002/14651858.CD002053.pub2. View

10.

Dryden C, Young D, Hepburn M, Mactier H . Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG. 2009; 116(5):665-71. DOI: 10.1111/j.1471-0528.2008.02073.x. View

11.

Kraft W, Gibson E, Dysart K, Damle V, Larusso J, Greenspan J . Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008; 122(3):e601-7. PMC: 2574639. DOI: 10.1542/peds.2008-0571. View

12.

Coghlan D, Milner M, Clarke T, Lambert I, McDermott C, McNally M . Neonatal abstinence syndrome. Ir Med J. 1999; 92(1):232-3, 236. View

13.

Mamelle N, Cochet V, Claris O . Definition of fetal growth restriction according to constitutional growth potential. Biol Neonate. 2001; 80(4):277-85. DOI: 10.1159/000047157. View

14.

Colombini N, Elias R, Busuttil M, Dubuc M, Einaudi M, Bues-Charbit M . Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone. Pharm World Sci. 2007; 30(3):227-34. DOI: 10.1007/s11096-007-9176-1. View

15.

Jansson L, Velez M, Harrow C . The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag. 2009; 5(1):47-55. PMC: 2729086. View

16.

Nandakumar N, Sankar V . What is the best evidence based management of neonatal abstinence syndrome?. Arch Dis Child Fetal Neonatal Ed. 2006; 91(6):F463. PMC: 2672769. DOI: 10.1136/adc.2006.095166. View

17.

SUTTON L, Hinderliter S . Diazepam abuse in pregnant women on methadone maintenance. Implications for the neonate. Clin Pediatr (Phila). 1990; 29(2):108-11. DOI: 10.1177/000992289002900208. View

18.

Langenfeld S, Birkenfeld L, Herkenrath P, Muller C, Hellmich M, Theisohn M . Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug Alcohol Depend. 2004; 77(1):31-6. DOI: 10.1016/j.drugalcdep.2004.07.001. View

19.

OGrady M, Hopewell J, White M . Management of neonatal abstinence syndrome: a national survey and review of practice. Arch Dis Child Fetal Neonatal Ed. 2009; 94(4):F249-52. DOI: 10.1136/adc.2008.152769. View

20.

Dysart K, Hsieh H, Kaltenbach K, Greenspan J . Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. J Perinat Med. 2007; 35(4):344-6. DOI: 10.1515/JPM.2007.063. View